Try

2seventy bio, Inc.

TSVTUnited States

15 filed reports · 294 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

FigureLatest fiscal yearLatest quarter
Revenue$37.9MFY2024 · to Dec 31, 2024−62.3% from $100M10-K$22.9MQ1 FY2025 · to Mar 31, 2025+84.5% from $12.4M10-Q
Net income-$57.2MFY2024 · to Dec 31, 2024a year earlier: -$218M10-K$482KQ1 FY2025 · to Mar 31, 2025a year earlier: -$52.7M10-Q
Operating income-$115MFY2024 · to Dec 31, 2024a year earlier: -$238M10-K-$2.52MQ1 FY2025 · to Mar 31, 2025a year earlier: -$51.2M10-Q

Filed reports

15 reports · Sep 2021 to Mar 2025

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR111,650Sep 2021 to Mar 2025
Annual · 10-KSEC EDGAR41,757Dec 2021 to Dec 2024

Documents

PeriodTypePeriod endPublishedFactsSource
FY2025 Q110-QMar 31, 2025May 7, 2025345Open
FY202410-KDec 31, 2024Mar 25, 2025561Open
FY2024 Q310-QSep 30, 2024Nov 12, 2024212Open
FY2024 Q210-QJun 30, 2024Aug 8, 2024169Open
FY2024 Q110-QMar 31, 2024May 9, 2024135Open
FY202310-KDec 31, 2023Mar 7, 2024532Open
FY2023 Q310-QSep 30, 2023Nov 14, 2023150Open
FY2023 Q210-QJun 30, 2023Aug 14, 2023123Open
FY2023 Q110-QMar 31, 2023May 10, 2023126Open
FY202210-KDec 31, 2022Mar 16, 2023344Open
FY2022 Q310-QSep 30, 2022Nov 7, 2022125Open
FY2022 Q210-QJun 30, 2022Aug 10, 2022103Open

Financial data

294 concepts · 3,407 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial276 concepts · 3,292 facts · Dec 2019 to Mar 2025

  • Cash cash equivalents restricted cash and restricted cash equivalents26 · Dec 2019 to Mar 2025
  • Allocated share based compensation expense25 · Dec 2019 to Mar 2025
  • Business combination contingent consideration arrangements change in amount of contingent consideration liability125 · Dec 2019 to Mar 2025
  • Cash and cash equivalents at carrying value25 · Dec 2019 to Mar 2025
  • Costs and expenses25 · Dec 2019 to Mar 2025
  • Income loss from continuing operations before income taxes extraordinary items noncontrolling interest25 · Dec 2019 to Mar 2025
  • Income tax expense benefit25 · Dec 2019 to Mar 2025
  • Net income loss25 · Dec 2019 to Mar 2025
  • Operating income loss25 · Dec 2019 to Mar 2025
  • Other nonoperating income expense25 · Dec 2019 to Mar 2025
  • Research and development expense25 · Dec 2019 to Mar 2025
  • Restricted cash and cash equivalents25 · Dec 2019 to Mar 2025
  • Revenue25 · Dec 2019 to Mar 2025
  • Revenue from collaborative arrangement excluding revenue from contract with customer25 · Dec 2019 to Mar 2025
  • Selling general and administrative expense25 · Dec 2019 to Mar 2025
  • Stockholders equity (US GAAP)25 · Dec 2019 to Mar 2025
  • Capital expenditures incurred but not yet paid24 · Dec 2019 to Mar 2025
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect24 · Dec 2019 to Mar 2025
  • Cost of goods and services sold (US GAAP)24 · Dec 2019 to Dec 2024
  • Depreciation depletion and amortization24 · Dec 2019 to Mar 2025
  • Increase decrease in accounts payable24 · Dec 2019 to Mar 2025
  • Increase decrease in accrued liabilities and other operating liabilities24 · Dec 2019 to Mar 2025
  • Increase decrease in contract with customer liability24 · Dec 2019 to Mar 2025
  • Increase decrease in operating lease liability24 · Dec 2019 to Mar 2025

Segment17 concepts · 63 facts · Dec 2023 to Mar 2025

  • Gain loss on disposition of assets14 · Dec 2023 to Mar 2025
  • Income (Loss) From Collaborative Arrangements4 · Dec 2023 to Mar 2025
  • Income tax expense benefit4 · Dec 2023 to Mar 2025
  • Infrastructure and Support Functions4 · Dec 2023 to Mar 2025
  • Interest income expense nonoperating net4 · Dec 2023 to Mar 2025
  • Manufacturing Costs Under Commercial Arrangements4 · Dec 2023 to Mar 2025
  • Net income loss4 · Dec 2023 to Mar 2025
  • Other nonoperating income expense4 · Dec 2023 to Mar 2025
  • Other research and development expense4 · Dec 2023 to Mar 2025
  • Payments for rent4 · Dec 2023 to Mar 2025
  • Restructuring Costs And Employee Benefits And Share-Based Compensation4 · Dec 2023 to Mar 2025
  • Revenue4 · Dec 2023 to Mar 2025
  • Revenue from collaborative arrangement excluding revenue from contract with customer4 · Dec 2023 to Mar 2025
  • Segment reporting other item amount4 · Dec 2023 to Mar 2025
  • Revenue from contracts with customers (excluding tax)3 · Dec 2023 to Mar 2025
  • Research and development expense2 · Dec 2023 to Dec 2024
  • Research And Development Expense, Adjusted2 · Mar 2024 to Mar 2025

Product1 concept · 52 facts · Mar 2019 to Mar 2025

  • Revenue52 · Mar 2019 to Mar 2025

Segments

115 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement business segments1 member · 63 facts

  • Reportable Segment63 · Dec 2023 to Mar 2025

Product or service2 members · 52 facts

  • Royalty and other revenue27 · Mar 2019 to Mar 2025
  • Service25 · Dec 2019 to Mar 2025

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of 2seventy bio, Inc. (TSVT) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.

2seventy bio, Inc. (TSVT): FY2024 revenue $37.9M · FactIQ